• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Using a molecular motor to switch the preference of anion-binding catalysts

Bioengineer by Bioengineer
December 6, 2019
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: R. Dorel / University of Groningen


Many organic molecules are chiral, which means that they are non-superimposable on their mirror image. Those mirror images are called enantiomers and can have different properties when interacting with other chiral entities, for example, biomolecules. Selectively producing the right enantiomer is therefore important in for example the pharmaceutical. University of Groningen chemists Ruth Dorel and Ben Feringa have now devised a method that not only achieves this but that also controls which version is being produced using light. The results were published online by the journal Angewandte Chemie on November 17.

The process is based on the use of a molecular motor created by Professor Feringa, for which he was awarded the 2016 Nobel Prize in Chemistry. The motor molecule was used to produce the first switchable catalyst for asymmetric anion-binding catalysis. Dr Ruth Dorel explains: ‘We attached anion-binding arms on both sides of the motor molecule to create an anion receptor that can act as a catalyst. This receptor will adopt a helical structure in the presence of anions that, depending on the relative position of the arms, will exist in different forms.’

Switch

In this study, a very slow-turning motor molecule was used so that different stages of the rotation cycle could be used in catalysis. The molecular motor is made up of two identical halves, linked by a double carbon-carbon bond that acts as the axle. By sequentially exposing the molecule to UV-light and heat, unidirectional rotation around the axle is achieved. Consequently, the anion-binding groups on both halves of the motor are able to switch from being apart from each other (trans) to being in close proximity on the same side of the motor molecule (cis). In the cis configuration, the arms can adopt two different configurations leading to two different helices with opposite handedness. Dorel: ‘The helicity dictates the enantiomer of the product that this catalyst will produce.’

Drugs or polymers

The new catalyst was tested on a benchmark reaction for anion-binding catalysis. ‘We now have a proof of principle,’ Dorel explains. Practical applications are a long way off but could potentially be found both in fundamental research and in the production of drugs or polymers. For many drugs, only one of the two mirror images is the active substance – the other may do nothing, or even cause side effects. ‘And in polymer production, a catalyst like this could alter the shape and properties of the polymer chain on demand.’

###

Reference: Ruth Dorel and Ben L. Feringa: Stereodivergent Anion Binding Catalysis with Molecular Motors. Angewandte Chemie International Edition, online 17 November 2019

Simple Science Summary

Many important molecules, for example, drugs, exist in two chemically identical forms that are each other’s mirror image, like a left and a right hand. These two ‘hands’ can have different properties: one may act as the drug, while the other produces side effects. By using catalysts, chemists can produce just one type of ‘hand’. University of Groningen scientists Ruth Dorel and Ben Feringa have now created a special catalyst that can switch between two forms that will produce one or the other ‘hand’. The switch is based on a molecular motor, a tiny machine that Feringa discovered.

Media Contact
Rene Fransen
[email protected]

Original Source

https://www.rug.nl/sciencelinx/nieuws/2019/12/using-a-molecular-motor-to-switch-the-preference-of-anion-binding-catalysts

Related Journal Article

http://dx.doi.org/10.1002/anie.201913054

Tags: BiochemistryChemistry/Physics/Materials SciencesNanotechnology/MicromachinesPharmaceutical ChemistryPharmaceutical SciencePharmaceutical SciencesPharmaceutical/Combinatorial ChemistryPolymer Chemistry
Share12Tweet8Share2ShareShareShare2

Related Posts

Tackling Ageism: Nurse Education Intervention Proven Effective

September 7, 2025

Childhood Trauma, HIV, and Women’s Mental Health Insights

September 7, 2025

9-Fluorenone Sulfonamides: Dual Inhibitors of SARS-CoV-2 Proteases

September 7, 2025

Shikonin Blocks EMT in Glioblastoma via p53 Activation

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.